Equities

Altamira Therapeutics Ltd

CYTO:NAQ

Altamira Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.499
  • Today's Change-0.006 / -1.19%
  • Shares traded24.16k
  • 1 Year change-78.60%
  • Beta2.4613
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, Altamira Therapeutics Ltd increased its cash reserves by 9,807.44%, or 540.39k. Cash Flow from Financing totalled 1.11m or 632.06% of revenues. In addition the company used 574.55k for operations while cash from investing totalled 2.30k.
Cash flow per share-2.42
Price/Cash flow per share--
Book value per share2.37
Tangible book value per share0.6333
More ▼

Balance sheet in USDView more

Altamira Therapeutics Ltd has a Debt to Total Capital ratio of 6.34%.
Current ratio0.4268
Quick ratio0.4268
Total debt/total equity0.0677
Total debt/total capital0.0634
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.